Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ustekinumab for Prevention of Graft Vs. Host Disease After Allogeneic Hematopoietic Cell Transplantation
NCT04572815Phase 2Active, not recruiting
- Sponsor
- Fred Hutchinson Cancer Center
- Start
- May 2021
- Primary completion
- Oct 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in graft-versus-host disease (GVHD) comparing Arm I (ustekinumab) with Arm II (placebo) (2 arms). Primary endpoint: Grade II-IV acute graft versus host disease (GVHD) survival at 6 months. Started May 2021; status: active, not recruiting.
02
Drugs
ustekinumab
03
Conditions
graft-versus-host disease (GVHD)
Beyond the preview
Go deeper on NCT04572815.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04572815.